Genomics Inform.  2020 Dec;18(4):e35. 10.5808/GI.2020.18.4.e35.

The nature of triple-negative breast cancer classification and antitumoral strategies

• Kim S
• Kim DH
• Lee W
• Lee YM
• Choi SY
• Han K

• KMID: 2510350
• DOI: http://doi.org/10.5808/GI.2020.18.4.e35

Abstract

Identifying the patterns of gene expression in breast cancers is essential to understanding their pathophysiology and developing anticancer drugs. Breast cancer is a heterogeneous disease with different subtypes determined by distinct biological features. Luminal breast cancer is characterized by a relatively high expression of estrogen receptor (ER) and progesterone receptor (PR) genes, which are expressed in breast luminal cells. In ~25% of invasive breast cancers, human epidermal growth factor receptor 2 (HER2) is overexpressed; these cancers are categorized as the HER2 type. Triple-negative breast cancer (TNBC), in which the cancer cells do not express ER/PR or HER2, shows highly aggressive clinical outcomes. TNBC can be further classified into specific subtypes according to genomic mutations and cancer immunogenicity. Herein, we discuss the brief history of TNBC classification and its implications for promising treatments.

Keyword

classification; gene expression; immune checkpoint blockade; microbiome; subtype; triple-negative breast cancer